Literature DB >> 6116649

Inhibition of leucocyte motility by drugs used in ulcerative colitis.

J M Rhodes, T C Bartholomew, D P Jewell.   

Abstract

The effects on leucocyte motility of sulphasalazine (Salazopyrin) and its metabolites sulphapyridine and 5 amino-salicylic acid have been compared with those of prednisolone and indomethacin. Sulphasalazine, its active metabolite 5 amino-salicylic acid, and prednisolone are all potent inhibitors of leucocyte motility. Sulphapyridine and indomethacin are non-inhibitory. Inhibition of leucocyte motility may explain why sulphasalazine and 5 amino-salicylic acid are effective in ulcerative colitis while sulphapyridine is not. The lack of effect of indomethacin suggests that this action of sulphasalazine does not involve inhibition of prostaglandin synthesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116649      PMCID: PMC1420067          DOI: 10.1136/gut.22.8.642

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  Criteria of viability of isolated liver cells.

Authors:  H Baur; S Kasperek; E Pfaff
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1975-06

2.  The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

Authors:  M A Peppercorn; P Goldman
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

3.  Distribution studies of salicylazosulfapyridine and its metabolites.

Authors:  M A Peppercorn; P Goldman
Journal:  Gastroenterology       Date:  1973-02       Impact factor: 22.682

4.  The effect of complement depletion on neutrophil migration in acute immunologic arthritis.

Authors:  C V DeShazo; M T McGrade; P M Henson; C G Cochrane
Journal:  J Immunol       Date:  1972-05       Impact factor: 5.422

5.  Characterization of the chemotactic activity of casein for neutrophil leucocytes and macrophages.

Authors:  P C Wilkinson
Journal:  Experientia       Date:  1972-09-15

6.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

Authors:  J R Vane
Journal:  Nat New Biol       Date:  1971-06-23

7.  Letter: Prostaglandins, ulcerative colitis, and sulphasalazine.

Authors:  S R Gould
Journal:  Lancet       Date:  1975-11-15       Impact factor: 79.321

8.  Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis.

Authors:  J Powell-Tuck; J E Lennard-Jones; C S May; C G Wilson; J W Paterson
Journal:  Br Med J       Date:  1976-01-24

9.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors:  A S Dissanayake; S C Truelove
Journal:  Gut       Date:  1973-12       Impact factor: 23.059

10.  The chemosuppression of chemotaxis.

Authors:  P A Ward
Journal:  J Exp Med       Date:  1966-08-01       Impact factor: 14.307

View more
  26 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 2.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

Review 3.  Drug management of ulcerative colitis.

Authors:  M A Kamm; A Senapati
Journal:  BMJ       Date:  1992-07-04

Review 4.  Phagocytes, toxic oxygen metabolites and inflammatory bowel disease: implications for treatment.

Authors:  J G Williams
Journal:  Ann R Coll Surg Engl       Date:  1990-07       Impact factor: 1.891

5.  Effect of sulphasalazine and its active metabolite, 5-amino-salicylic acid, on toxic oxygen metabolite production by neutrophils.

Authors:  J G Williams; M B Hallett
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

Review 6.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

7.  The application of RNAi-based treatments for inflammatory bowel disease.

Authors:  Morten Tobias Jarlstad Olesen; Borja Ballarín-González; Kenneth Alan Howard
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

8.  Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.

Authors:  C Wahl; S Liptay; G Adler; R M Schmid
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

9.  Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

Authors:  C J Hawkey; N K Boughton-Smith; B J Whittle
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

10.  Sulphasalazine in the treatment of children with chronic arthritis.

Authors:  J L Huang; L C Chen
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.